HomeVALN • NASDAQ
Valneva SE
add
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 49.23M | 50.31% |
Operating expense | 17.20M | 124.31% |
Net income | -9.23M | -115.67% |
Net profit margin | -18.75 | -110.42% |
Earnings per share | -0.14 | -115.41% |
EBITDA | -2.28M | -103.21% |
Effective tax rate | -19.00% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 152.99M | -13.39% |
Total assets | 482.24M | -4.09% |
Total liabilities | 306.99M | -2.11% |
Total equity | 175.25M | — |
Shares outstanding | 153.87M | — |
Price to book | 5.40 | — |
Return on assets | -3.03% | — |
Return on capital | -3.80% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -9.23M | -115.67% |
Cash from operations | -8.15M | 71.34% |
Cash from investing | -961.00K | -101.11% |
Cash from financing | -5.58M | 25.14% |
Net change in cash | -15.28M | -130.22% |
Free cash flow | -19.68M | -198.73% |
Previous close
$6.16
Day range
$6.23 - $6.37
Year range
$3.62 - $9.50
Market cap
535.53M USD
Avg Volume
96.69K
About
Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States. Wikipedia
Founded
2013
Website
Employees
713
